News

Sarepta initiated with a bullish view at Wells Fargo on Elevidys
Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...
Fintel on MSN7d
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation
Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...
Sarepta initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...
Investing7d
Wells Fargo sets Sarepta stock price target at $115
On Friday, Wells Fargo (NYSE:WFC) initiated coverage on Sarepta Therapeutics (NASDAQ:SRPT), currently trading at $50.31, assigning an Overweight rating to the biopharmaceutical company with a price ...
Nasdaq18d
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation
Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Overweight recommendation. As of April 1, 2025, the average one-year price ...
Nasdaq8d
Wells Fargo Initiates Coverage of Sarepta Therapeutics (BMV:SRPT) with Overweight Recommendation
Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (BMV:SRPT) with a Overweight recommendation. There are 956 funds or institutions reporting positions ...